Aflibercept 8 mg shows comparable IOP safety to 2 mg through 96 weeks
A pooled analysis of the phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume than aflibercept 2 mg, was not associated with…
Latest Videos
See AllExplore Topic Centers
Anterior Segment
Cataract
Cornea and External Disease
Diabetic Macular Edema
Dry Eye
Early Onset Cataracts
Exclusives
General
Geographic Atrophy
Glaucoma
Industry News
Ocular Surface Disease
Oculoplastics
Pediatrics
Practice Management
Presbyopia
Refractive Surgery/Vision Correction
Residents & Young Ophthalmologists
Retina
Retinopathy of Prematurity
Trending Topics



















